In this study, using publicly available transcriptome expression data from the TCGA, we evaluated the modifications in the hub proteins, such as polo like kinase 1 (PLK1), cell division cycle 20 (CDC20), caveolin 1 (CAV1), camodulin 1 (CALM1), and p21 activated kinase 3 (PAK3), in relation to their clinical significance and determined which categories of immune cells have been associated with poorly differentiated prostate adenocarcinomas, as indicated by high Gleason scores. The gene discussed is PLK1; the disease is prostate adenocarcinoma.